시장보고서
상품코드
1593532

저분자 API 시장 규모, 점유율, 성장 분석(유형별, 제조업체별, 용도별, 지역별) : 산업 예측(2024-2031년)

Small Molecule API Market Size, Share, Growth Analysis, By Type (Synthetic, Biotech), By Manufacturer (In-house, Outsourced), By Application (Cardiology, Oncology), By Region - Industry Forecast 2024-2031

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 172 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 저분자 API(저분자 원료의약품) 시장 규모는 2022년에 1,848억 5,000만 달러로 평가되며, 2023년 1,949억 달러에서 2031년에는 2,977억 6,000만 달러로 확대하며, 예측 기간(2024-2031년)에 5.44%의 CAGR로 성장할 전망입니다.

세계 저분자 원료의약품(API) 시장은 만성질환 유병률 증가와 신약개발 투자 증가에 힘입어 큰 폭의 성장이 예상되고 있습니다. 오리지널 의약품의 가격 상승은 제네릭 의약품으로의 전환을 촉진하고 있으며, 저분자 API에 대한 수요는 앞으로 더욱 증가할 것으로 예상됩니다. 또한 API 합성 기술의 발전과 저분자 연구에 대한 투자 증가는 API 공급업체에게 새로운 기회를 제공합니다. 저렴한 가격의 암 치료제에 대한 수요 증가는 전 세계에서 시장 확대를 촉진할 것으로 예상됩니다. 그러나 복잡한 제조 공정, 높은 제조 비용, 엄격한 규제 프레임워크 등의 문제는 향후 시장 수요를 저해할 수 있는 요인으로 작용할 수 있습니다. 그럼에도 불구하고 지속가능하고 지속적인 제조 방식에 대한 관심이 높아지면서 진화하는 시장 환경에서 기업이 혁신하고 성공할 수 있는 잠재적 경로를 제공합니다. 이러한 요인의 수렴은 저분자 API 부문의 역동적인 미래를 암시하며, 내재된 도전을 극복하고 새로운 기회를 활용하기 위한 전략적 적응의 필요성을 강조하고 있습니다.

목차

서론

  • 조사의 목적
  • 정의
  • 시장 범위

조사 방법

  • 정보 조달
  • 2차 데이터 소스와 1차 데이터 소스
  • 시장 규모 예측
  • 시장의 상정과 제한

개요

  • 시장 개요 전망
  • 공급 수요 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 역학
    • 촉진요인
    • 기회
    • 억제요인
    • 과제
  • Porter의 산업 분석

주요 시장 인사이트

  • 주요 성공 요인
  • 경쟁의 정도
  • 주요 투자 기회
  • 시장의 에코시스템
  • 모시장 분석
  • PESTEL 분석
  • 규제 상황

저분자 API 시장 : 유형별

  • 시장 개요
  • 합성
  • 바이오테크

저분자 API 시장 : 제조업체별

  • 시장 개요
  • 사내
  • 아웃소싱

저분자 API 시장 : 용도별

  • 시장 개요
  • 심장병학
  • 종양학
  • 중추신경계·신경학
  • 정형외과
  • 내분비학
  • 호흡기과
  • 소화기 내과
  • 신장학
  • 안과
  • 기타

저분자 API 시장 : 지역별

  • 시장 개요
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카(MEA)
    • 걸프협력회의(GCC) 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 구도

  • 상위 5사의 비교
  • 주요 기업의 시장 포지셔닝(2023년)
  • 주요 시장 기업이 채택한 전략
  • 시장에서의 최근 활동
  • 주요 기업의 시장 점유율(2023년)

주요 기업 개요

  • Johnson Matthey(영국)
  • Pfizer Inc.(미국)
  • Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd.(중국)
  • Sanofi S.A.(프랑스)
  • Novartis AG(스위스)
  • Bristol-Myers Squibb(미국)
  • Boehringer Ingelheim GmbH(독일)
  • GlaxoSmithKline PLC(영국)
  • GILEAD Sciences Inc.(미국)
  • Albany Molecular Research Inc.(미국)
  • AstraZeneca(영국)
  • Merck & Co. Inc.(미국)
  • BASF SE(독일)
  • Teva Pharmaceuticals(이스라엘)
  • Hoffmann-La Roche Ltd.(스위스)
  • Albemarle Corporation(미국)
  • AbbVie(미국)
  • Aurobindo Pharma(인도)
  • Cambrex Corporation(미국)
  • Dr. Reddy's Laboratories Ltd.(인도)
  • Lonza(스위스)
  • Merck KGaA(독일)
  • Siegfried Holding AG(스위스)
  • Sun Pharmaceutical Industries Ltd.(인도)
KSA 24.12.02

Global Small Molecule API Market size was valued at USD 184.85 billion in 2022 and is poised to grow from USD 194.90 billion in 2023 to USD 297.76 billion by 2031, growing at a CAGR of 5.44% in the forecast period (2024-2031).

The global landscape for small molecule active pharmaceutical ingredients (APIs) is poised for significant growth, driven by the rising prevalence of chronic diseases and increased investments in drug discovery and development. The soaring prices of branded medications are fueling a shift towards generic drugs, which is anticipated to further enhance the demand for small molecule APIs in the coming years. Additionally, advancements in API synthesis technologies and heightened investment in small molecule research present new opportunities for API suppliers. The escalating need for affordable oncology medications is also expected to stimulate market expansion on a worldwide scale. However, challenges such as the complexity of manufacturing processes, high production costs, and stringent regulatory frameworks may hinder market demand moving forward. Nonetheless, a growing focus on sustainable and continuous manufacturing methodologies offers potential avenues for small molecule API companies to innovate and thrive in the evolving market landscape. This convergence of factors signals a dynamic future for the small molecule API sector, emphasizing the need for strategic adaptations to leverage emerging opportunities while navigating inherent challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Small Molecule Api market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Small Molecule Api Market Segmental Analysis

Global Small Molecule API Market is segmented on the type, manufacturer, application, and region. By type, the market is segmented into Synthetic and Biotech. By manufacturer, the market is segmented into In-house and Outsourced. By application, the market is segmented into Cardiology, Oncology, CNS and Neurology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, and Others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Small Molecule Api Market

The rising prevalence of chronic disorders attributable to poor lifestyle choices is a significant market driver for the Global Small Molecule API market. As an increasing number of individuals grapple with conditions such as diabetes, cardiovascular diseases, and obesity, the demand for effective pharmaceutical interventions continues to surge. This growing need for targeted therapies propels the production and utilization of small molecule active pharmaceutical ingredients (APIs), known for their efficacy in treating a wide range of ailments. Consequently, the sustained expansion of healthcare expenditures and a focus on innovative drug development strategies further reinforce the momentum of the small molecule API market globally.

Restraints in the Global Small Molecule Api Market

The Global Small Molecule API market faces significant restraints due to the high manufacturing costs associated with the production of small molecule APIs. The process necessitates specialized equipment and facilities, which demand substantial capital investment. Additionally, the requirement for skilled professionals to operate such equipment further escalates operational costs. The reliance on expensive raw materials compounds these financial burdens, ultimately limiting the ability of manufacturers to scale production competitively. This cost-intensive aspect not only hinders market entry for new players but also restricts expansion opportunities for existing companies, thereby stifling overall market growth and development potential.

Market Trends of the Global Small Molecule Api Market

The Global Small Molecule API market is increasingly influenced by the rise of personalized medicine, driving a significant market trend towards tailored therapeutic solutions. As healthcare transitions to individualized treatment plans, small molecule API providers are optimizing their business models to address specific patient needs and niche markets. This shift is facilitating the development of innovative small molecule APIs that target unique biomarkers and genetic profiles, promising substantial returns for industry players. Consequently, this trend not only enhances treatment efficacy but also positions companies to thrive in a competitive landscape, thereby shaping the future of the pharmaceutical industry.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factor
  • Degree of Competition
  • Top Investment Pockets
  • Ecosystem of the Market
  • Parent Market Analysis
  • PESTEL Analysis
  • Regulatory Landscape

Small Molecule API Market, By Type

  • Market Overview
  • Synthetic
  • Biotech

Small Molecule API Market, By Manufacturer

  • Market Overview
  • In-house
  • Outsourced

Small Molecule API Market, By Application

  • Market Overview
  • Cardiology
  • Oncology
  • CNS and Neurology
  • Orthopedic
  • Endocrinology
  • Pulmonology
  • Gastroenterology
  • Nephrology
  • Ophthalmology
  • Others

Small Molecule API Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Johnson Matthey (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline PLC (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GILEAD Sciences Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Albany Molecular Research Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co. Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BASF SE (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceuticals (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hoffmann-La Roche Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Albemarle Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aurobindo Pharma (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cambrex Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dr. Reddy's Laboratories Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lonza (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Siegfried Holding AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제